Clinical Trial

Neuroimmunology Registry and Biobank

Recruiting
View on ClinicalTrials.gov →
Summary
A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain. The registry was established with the following objectives: \[1\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \[2\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \[3\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \[4\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.
Trial Details
NCT Number NCT06958341
Lead Sponsor Charite University, Berlin, Germany
Collaborators: University of Ulm
Conditions Encephalopathy, Psychosis, Impaired Consciousness, Epilepsy, Movement Disorders, Motor Neuropathy, Spasticity, Ataxia
Enrollment 300 participants
Start Date 2021-02-01
Primary Completion 2031-01-01 (estimated)
Study Completion 2031-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-06